NO20015864D0 - Blokkerende monoklonalt antistoff mot VLA-1 samt anvendelse derav ved behandling av inflammatoriske lidelser - Google Patents

Blokkerende monoklonalt antistoff mot VLA-1 samt anvendelse derav ved behandling av inflammatoriske lidelser

Info

Publication number
NO20015864D0
NO20015864D0 NO20015864A NO20015864A NO20015864D0 NO 20015864 D0 NO20015864 D0 NO 20015864D0 NO 20015864 A NO20015864 A NO 20015864A NO 20015864 A NO20015864 A NO 20015864A NO 20015864 D0 NO20015864 D0 NO 20015864D0
Authority
NO
Norway
Prior art keywords
vla
treatment
monoclonal antibody
inflammatory disorders
blocking monoclonal
Prior art date
Application number
NO20015864A
Other languages
English (en)
Other versions
NO20015864L (no
Inventor
Antonin De Fougerolles
Philip Gotwals
Roy R Lobb
Victor Koteliansky
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO20015864D0 publication Critical patent/NO20015864D0/no
Publication of NO20015864L publication Critical patent/NO20015864L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
NO20015864A 1999-06-01 2001-11-30 Blokkerende monoklonalt antistoff mot VLA-1 samt anvendelse derav ved behandling av inflammatoriske lidelser NO20015864L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13703899P 1999-06-01 1999-06-01
US18533600P 2000-02-29 2000-02-29
PCT/US2000/015004 WO2000072881A1 (en) 1999-06-01 2000-06-01 A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
NO20015864D0 true NO20015864D0 (no) 2001-11-30
NO20015864L NO20015864L (no) 2002-02-01

Family

ID=26834850

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015864A NO20015864L (no) 1999-06-01 2001-11-30 Blokkerende monoklonalt antistoff mot VLA-1 samt anvendelse derav ved behandling av inflammatoriske lidelser

Country Status (28)

Country Link
US (5) US6955810B2 (no)
EP (3) EP1181054A1 (no)
JP (6) JP4817503B2 (no)
CN (1) CN1309419C (no)
AU (2) AU783989B2 (no)
BG (1) BG65579B1 (no)
BR (1) BR0011250A (no)
CA (1) CA2375827C (no)
CY (1) CY1116042T1 (no)
CZ (1) CZ300710B6 (no)
DK (2) DK1488806T3 (no)
EA (1) EA011384B1 (no)
EE (1) EE200100651A (no)
ES (2) ES2557768T3 (no)
GE (1) GEP20063774B (no)
HK (2) HK1043320A1 (no)
HU (1) HUP0202568A3 (no)
IL (2) IL146508A0 (no)
IS (1) IS6179A (no)
MX (1) MXPA01012388A (no)
NO (1) NO20015864L (no)
NZ (1) NZ515686A (no)
PT (2) PT1488806E (no)
SI (2) SI1488806T1 (no)
SK (1) SK17232001A3 (no)
TR (1) TR200103432T2 (no)
WO (1) WO2000072881A1 (no)
YU (1) YU85501A (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2557768T3 (es) 1999-06-01 2016-01-28 Biogen Ma Inc. Un anticuerpo monoclonal bloqueante frente a VLA-1 y su uso para el tratamiento de trastornos inflamatorios
IL158376A0 (en) 2001-04-13 2004-05-12 Biogen Inc Antibodies to vla-1
AU2003215298A1 (en) * 2002-02-14 2003-09-04 Biogen, Inc. Alpha1beta1 antagonists for treatment of atherosclerosis
AU2003287435A1 (en) * 2002-11-01 2004-06-07 Boys Town Nat Res Hospital INDUCIBLE LIGAND FOR Alpha1Beta1 INTEGRIN AND USES
WO2005004800A2 (en) * 2003-06-20 2005-01-20 Morehouse School Of Medicine Trypanosome derived apoptotic factors (taf)
US20080093950A1 (en) * 2003-12-09 2008-04-24 Electrotechnologies Selem. Inc Polyphase Claw-Pole Machines With a Segmented Magnetic Circuit
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en) * 2005-06-07 2006-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment of tnf antagonist-resistant inflammatory disorders and related methods
PL2034830T3 (pl) * 2006-05-25 2015-04-30 Biogen Ma Inc Przeciwciało anty-VLA-1 do leczenia udaru
WO2009135953A2 (en) * 2008-05-09 2009-11-12 Ablynx Nv Amino acid sequences directed against integrins and uses thereof
KR102167261B1 (ko) * 2010-06-18 2020-10-20 엑스바이오테크, 인크. 관절염 치료
US10316095B2 (en) 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
US11312775B2 (en) 2017-07-20 2022-04-26 University Of Virginia Patent Foundation Methods for treatment or prevention of a neurological immunity disorder

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988007089A1 (en) * 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1991010737A1 (en) * 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5391481A (en) * 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
US5871907A (en) * 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DK0626861T4 (da) 1992-01-13 2004-08-16 Biogen Inc Behandling af astma.
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
ES2114183T5 (es) 1993-02-09 2006-06-16 Biogen Idec Ma, Inc. Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
US6111598A (en) * 1993-11-12 2000-08-29 Peveo, Inc. System and method for producing and displaying spectrally-multiplexed images of three-dimensional imagery for use in flicker-free stereoscopic viewing thereof
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ES2270425T3 (es) 1994-01-25 2007-04-01 Elan Pharmaceuticals, Inc. Anticuerpos humanizados contra la molecula de adhesion leucocitaria vla-4.
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
ES2151054T3 (es) * 1994-04-26 2000-12-16 Kanebo Ltd Farmaco para el tratamiento de la artritis reumatoide.
JPH08131185A (ja) * 1994-11-14 1996-05-28 Sumitomo Electric Ind Ltd マウスｖｌａ−１分子に対するモノクローナル抗体
JPH08160972A (ja) 1994-12-01 1996-06-21 Sega Enterp Ltd エフェクト制御方法、制御装置およびこれを利用したカラオケ装置
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
GB9516399D0 (en) 1995-08-10 1995-10-11 Camelot Superabsorbents Ltd Process for the production of water-absorbing compositions
WO1997008320A1 (en) * 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
DK0843961T3 (da) 1995-08-29 2007-05-21 Kirin Brewery Kimærisk mus og fremgangsmåde til at producere samme
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
GB9519667D0 (en) 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
FR2745912B1 (fr) * 1996-03-08 1998-05-29 Lorraine Laminage Procede et dispositif de controle de la soudabilite de toles sandwich
US6127524A (en) * 1996-10-18 2000-10-03 Dade Behring Inc. Binding molecules and computer-based methods of increasing the binding affinity thereof
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
DE69810481T2 (de) 1997-06-13 2003-09-25 Genentech Inc Stabilisierte antikörperformulierung
PL345946A1 (en) 1998-05-22 2002-01-14 Boys Town Nat Res Hospital Use of α1β1 integrin receptor inhibitors and tgf-β1 inhibitors in the treatment of kidney disease
DE19831710A1 (de) * 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
CA2340333A1 (en) 1998-10-06 2000-04-13 Biogen, Inc. Crystals of the alpha 1 beta 1 integrin i-domain and their use
IL145898A0 (en) * 1999-04-22 2002-07-25 Biogen Inc Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
ES2557768T3 (es) 1999-06-01 2016-01-28 Biogen Ma Inc. Un anticuerpo monoclonal bloqueante frente a VLA-1 y su uso para el tratamiento de trastornos inflamatorios
WO2000078221A1 (de) 1999-06-17 2000-12-28 Kai Desinger Chirurgische sonde zur minimal invasiven gewebeentnahme
WO2001073444A2 (en) 2000-03-28 2001-10-04 Cambridge University Technical Services Limited Receptor/peptide crystal structure for identification of inhibitors
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DE10028402A1 (de) 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
US7153944B2 (en) 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
IL158376A0 (en) 2001-04-13 2004-05-12 Biogen Inc Antibodies to vla-1
AU2003215298A1 (en) 2002-02-14 2003-09-04 Biogen, Inc. Alpha1beta1 antagonists for treatment of atherosclerosis
CA2494310A1 (en) 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040208870A1 (en) 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
WO2005016883A2 (en) 2003-08-14 2005-02-24 Icos Corporation Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
WO2005019200A2 (en) 2003-08-14 2005-03-03 Icos Corporation Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en) 2005-06-07 2006-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment of tnf antagonist-resistant inflammatory disorders and related methods
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
PL2034830T3 (pl) 2006-05-25 2015-04-30 Biogen Ma Inc Przeciwciało anty-VLA-1 do leczenia udaru
JP4951596B2 (ja) 2008-07-31 2012-06-13 株式会社日立製作所 冷却システム及び電子装置
CA2754528A1 (en) 2009-03-06 2010-09-10 Genetech, Inc. Antibody formulation
CN107095846A (zh) 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
US20140017261A1 (en) 2011-02-03 2014-01-16 Mark Totoritis Selection and treatment of subjects
CN103380495B (zh) 2012-01-11 2016-05-18 松下知识产权经营株式会社 压接型半导体装置及其制造方法
US10316095B2 (en) 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations

Also Published As

Publication number Publication date
NZ515686A (en) 2005-01-28
YU85501A (sh) 2004-07-15
US6955810B2 (en) 2005-10-18
ES2529706T3 (es) 2015-02-24
IS6179A (is) 2001-11-28
US20050226877A1 (en) 2005-10-13
EP2314315B1 (en) 2015-01-21
JP2012176983A (ja) 2012-09-13
BR0011250A (pt) 2002-03-05
JP4817503B2 (ja) 2011-11-16
EA200400930A1 (ru) 2004-12-30
HK1154352A1 (en) 2012-04-20
PT2314315E (pt) 2015-03-17
US9902774B2 (en) 2018-02-27
ES2557768T3 (es) 2016-01-28
JP2011157403A (ja) 2011-08-18
US8084031B2 (en) 2011-12-27
SI2314315T1 (sl) 2015-04-30
US20090324598A1 (en) 2009-12-31
US20140154259A1 (en) 2014-06-05
BG106226A (en) 2002-08-30
EP1488806B1 (en) 2015-12-09
US8557240B2 (en) 2013-10-15
BG65579B1 (bg) 2009-01-30
CY1116042T1 (el) 2017-01-25
AU2006201540A1 (en) 2006-05-11
EE200100651A (et) 2003-02-17
JP2004500328A (ja) 2004-01-08
CZ20014249A3 (cs) 2002-06-12
US20020146417A1 (en) 2002-10-10
WO2000072881A1 (en) 2000-12-07
IL146508A0 (en) 2002-07-25
HUP0202568A3 (en) 2009-11-30
GEP20063774B (en) 2006-03-27
EP1488806A3 (en) 2011-03-30
CA2375827A1 (en) 2000-12-07
US20120087925A1 (en) 2012-04-12
JP2007277253A (ja) 2007-10-25
EA011384B1 (ru) 2009-02-27
EP1488806A2 (en) 2004-12-22
AU783989B2 (en) 2006-01-12
CN1309419C (zh) 2007-04-11
US7462353B2 (en) 2008-12-09
EP2314315A1 (en) 2011-04-27
SK17232001A3 (sk) 2002-09-10
CN1390137A (zh) 2003-01-08
NO20015864L (no) 2002-02-01
EP1181054A1 (en) 2002-02-27
IL146508A (en) 2007-08-19
SI1488806T1 (sl) 2016-02-29
HUP0202568A2 (hu) 2002-11-28
MXPA01012388A (es) 2002-07-30
CA2375827C (en) 2017-01-10
JP5960762B2 (ja) 2016-08-02
DK1488806T3 (en) 2016-02-08
CZ300710B6 (cs) 2009-07-22
AU5724800A (en) 2000-12-18
JP2014210818A (ja) 2014-11-13
JP5623335B2 (ja) 2014-11-12
HK1043320A1 (zh) 2002-09-13
PT1488806E (pt) 2016-02-26
TR200103432T2 (tr) 2002-10-21
DK2314315T3 (en) 2015-02-02
JP2016121184A (ja) 2016-07-07

Similar Documents

Publication Publication Date Title
NO20016035L (no) Anvendelse av antistoff mot CD20 ved behandling av avstötning av implantanter
NO20015864L (no) Blokkerende monoklonalt antistoff mot VLA-1 samt anvendelse derav ved behandling av inflammatoriske lidelser
ZA963287B (en) Modified anti-icam-1 antibodies and their use in the treatment of inflammation
NO20013340L (no) Antagonister for TWEAK og for TWEAK-reseptor samt anvendelse derav ved behandling av immunologiske lidelser
NO20022174L (no) Anvendelse av anti-CD40L-antistoff i kombinasjon med anti- CD20-antistoff og/eller kjemoterapeutika og radioterapi vedbehandling av B-cellesykdommer
NO995095L (no) Substituerte imidazoler nyttig ved behandlingen av inflammasjonssykdommer
NO20024682D0 (no) Kombinert anvendelse av anti-cytokin-antistoff eller antagonister og anti-CD20 ved behandling av B-celle-lymfom
AU7566991A (en) Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
NO20034805L (no) CRIPTO-blokkerende antistoff samt anvendelse derav
CY2006007I2 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
NO960956L (no) Rekombinante IL4-antistoffer anvendelige ved behandling av IL4-betingede forstyrrelser
HUP0101151A3 (en) Monoclonal antibody anti alphav-integrin and its use to inhibit alphavbetha6-integrin attachment to fibnronectin
EP1085906A4 (en) ANTIBODIES AGAINST CYTOKINS FOR THE PREVENTION AND TREATMENT OF INFLAMMABLE INTESTINAL DISEASES
FI944521A0 (fi) Sulkuvälineillä varustettu terveysside
DE69914716D1 (de) Befestigungselement mit Halterungs- und Vorpositionierungsvorsprüngen des Stiftes
AU2003271681A8 (en) Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
FR2786096B1 (fr) Composition pour la prevention et le traitement topique de la cellulite
ZA200109273B (en) A blocking monoclonal antibody to VLA-1 and its use for the treatment of inflammatory disorders.
EP1646402A4 (en) ANTIBODIES TO THE FBSA PROTEIN OF STREPTOCOCCUS AGALACTIAE AND THEIR USE IN THE TREATMENT OR PREVENTION OF INFECTIONS
HUP0200354A3 (en) Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
TR199901676A3 (tr) Siddetli agrilarin giderilmesinde steroid olmayan enflamasyona karsi ilaçlarin kullanimi.
DK75794A (da) Fryseapparat samt anvendelse af samme
FI7U1 (fi) Formvaegg foer anvaendning vid framstaellning av betongelement

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application